Gab Adapter Proteins as Therapeutic Targets for Hematologic Disease
Author(s) -
Sheetal Verma,
Tamisha Vaughan,
Kevin D. Bunting
Publication year - 2011
Publication title -
advances in hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.371
H-Index - 31
eISSN - 1687-9112
pISSN - 1687-9104
DOI - 10.1155/2012/380635
Subject(s) - signal transducing adaptor protein , medicine , signal transduction , cancer research , computational biology , receptor , docking (animal) , immune system , drug , phosphorylation , cancer , immunology , microbiology and biotechnology , biology , pharmacology , nursing
The Grb-2 associated binder (Gab) family of scaffolding/adaptor/docking proteins is a group of three molecules with significant roles in cytokine receptor signaling. Gabs possess structural motifs for phosphorylation-dependent receptor recruitment, Grb2 binding, and activation of downstream signaling pathways through p85 and SHP-2. In addition, Gabs participate in hematopoiesis and regulation of immune response which can be aberrantly activated in cancer and inflammation. The multifunctionality of Gab adapters might suggest that they would be too difficult to consider as candidates for “targeted” therapy. However, the one drug/one target approach is giving way to the concept of one drug/multiple target approach since few cancers are addicted to a single signaling molecule for survival and combination drug therapies can be problematic. In this paper, we cover recent findings on Gab multi-functionality, binding partners, and their role in hematological malignancy and examine the concept of Gab-targeted therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom